Skip to main content
. 2011 Sep 13;52(10):7248–7255. doi: 10.1167/iovs.11-7398

Figure 4.

Figure 4.

Impact of combined B-Raf and MEK inhibition on BRAF-mutant and Gα-mutant UM cells. The BRAF-mutant OCM3 cells (A) and the Gα-mutant OMM1.3 (B) and Mel202 cells were treated with the combination of PLX4720 and AZD6244 at the indicated concentrations for 96 hours in medium containing 10% FBS. Cell number was quantified with the MTT assay and expressed as a percentage of control wells (average ± SD). In BRAF-mutant OCM3 cells, the combination of sublethal concentrations of PLX4720 and AZD6244 resulted in synergistic anticancer activity (A) , whereas in Gα-mutant OMM1.3 cells (B) and Mel202 cells (not shown), the addition of AZD6244 could not overcome their resistance to PLX4720.